Tirzepatide

Retatrutide is a synthetic multi-receptor binding peptide currently under investigation in preclinical research models. Published studies examine its receptor affinity profile across GLP-1, GIP, and glucagon receptor constructs. All research data referenced on this page derives from third-party published literature. Pepticore supplies this compound exclusively as a laboratory reference material. No biological outcomes or suitability for human use is implied or established.

The structural development of Retatrutide builds on earlier peptide research examining single and dual receptor binding constructs. Prior research investigated GLP-1 receptor binding profiles, followed by dual-receptor analogs. Retatrutide extends this structural framework by integrating GLP-1R, GIPR, and GcgR binding affinity into a single synthetic reference compound studied in in vitro laboratory assays.

Peer-reviewed literature has examined Retatrutide's binding characteristics across the following in vitro assay categories:

• Receptor binding assays: GLP-1R, GIPR, GcgR affinity and selectivity profiling
• In vitro endocrine pathway studies: Receptor interaction modeling
• Hepatic receptor pathway assays: Lipid pathway receptor mapping
• Multi-receptor signaling studies: Combinatorial receptor binding analysis

All findings referenced here are sourced from third-party peer-reviewed publications. Pepticore makes no independent claims regarding biological activity, efficacy, or outcomes for this compound.

Published literature on Retatrutide's structural properties is accessible via PubMed (CAS: 2381089-83-2). Analytical documentation available on our Certificate of Analysis page.